Celgene Corporation is in the biotechnology industry and was inaugurated in 1986. Two scientists, Sol J. Barer and David Stirling, came together to bring to life what seemed like a promising innovation in the biotechnology industry.
Since its inception, the American biotechnology company located in Summit, New Jersey, has made numerous discoveries. This has led to the development and commercialization of a wide range of cancer medicines as well as inflammatory disorders.
Celgene Corporation is a platform for growing and evolving patient outcomes. Its core business is in innovative therapies and the provision of supportive programs to enable access to these therapies. It has a unique perspective regarding research and development, which serves as the backbone of its discoveries.
The company’s principal commitment is in delivering proper infrastructure with new options for treating rare diseases. This happens from its entrepreneurial spirit, commitment, and a teamwork-oriented culture to transform lives. Celgene is listed in the NASDAQ market.
Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.